In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: data from GLORIA-AF

Session Poster Session 3

Speaker Gregory Yh Lip

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session
  • FP Number : P2896

Authors : JL Halperin (New York,US), C Teutsch (Ingelheim,DE), MV Huisman (Leiden,NL), H-C Diener (Essen,DE), KJ Rothman (North Carolina,US), CS Ma (Beijing,CN), SJ Dubner (Buenos Aires,AR), K Zint (Ingelheim,DE), L Riou Franca (Ridgefield, CT,US), M Paquette (Ontario,CA), GYH Lip (Birmingham,GB)

J.L. Halperin1 , C. Teutsch2 , M.V. Huisman3 , H.-C. Diener4 , K.J. Rothman5 , C.S. Ma6 , S.J. Dubner7 , K. Zint8 , L. Riou Franca9 , M. Paquette10 , G.Y.H. Lip11 , 1Mount Sinai School of Medicine - New York - United States of America , 2Boehringer Ingelheim International GmbH - Ingelheim - Germany , 3Leiden University Medical Center - Leiden - Netherlands , 4University Hospital Essen - Essen - Germany , 5RTI Health Solutions - Research Triangle Park - United States of America , 6Beijing Anzhen Hospital - Beijing - China People's Republic of , 7Clinic and Maternity Suizo Argentina - Buenos Aires - Argentina , 8Boehringer Ingelheim GmbH - Ingelheim - Germany , 9Boehringer Ingelheim Corporation - Ridgefield, CT - United States of America , 10Boehringer Ingelheim Corporation - Burlington - Canada , 11University of Birmingham - Birmingham - United Kingdom ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 610

Background: Patients with atrial fibrillation (AF) have a high prevalence of coronary artery disease (CAD) ranging from 18% to 47%, due to common risk factors such as older age, hypertension and diabetes. Oral anticoagulation is required for AF patients with moderate-to-high stroke risk. The safety and effectiveness of dabigatran etexilate (dabigatran) for stroke prevention in AF has been shown in randomized trials and numerous database studies. Prospective data from routine clinical practice are less common.

Purpose: This analysis from the global registry program GLORIA-AF describes clinical outcomes of dabigatran for up to 2 years in newly diagnosed AF patients with or without history of CAD.

Methods: GLORIA-AF is a prospective, observational global registry of patients with newly diagnosed AF and a CHA2DS2-VASc score of ≥1. Patients prescribed dabigatran at baseline were followed for up to 2 years. CAD is defined here as history of coronary artery disease, myocardial infarction or angina pectoris. Baseline characteristics and event rates (incidence rates with 95% CI) in patients on dabigatran with and without a history of CAD are reported.

Results: Overall, 4873 patients were prescribed dabigatran and 4859 received it for an average of 18.3±9.2 months. Of these, 3643 patients had no history of CAD, while 1091 had CAD (for 125 patients CAD history was unknown). Compared with patients with no CAD, patients with CAD were more often male (64.7 vs 53.1%); older (mean age: 71.9 vs 69.6 years), had a higher mean CHA2DS2-VASc score (3.8 vs 3.0) and a higher mean HAS-BLED score (1.5 vs 1.2). Concurrent antiplatelet therapy was more common in patients with CAD than without, 32.2% versus 7.0%, respectively. For patients with CAD or without CAD the crude incidence rates of stroke were 0.65 and 0.68 per 100 patient-years, respectively. Major bleeding rates were 1.42 and 0.86 per 100 patient-years. Intracranial bleed rates were low with 0.06 and 0.20 per 100 patient-years in patients with or without CAD, respectively [see table for further outcomes]. Incidence rates standardized by stroke and bleeding risk will be presented.

Conclusion: This analysis provides insights on newly diagnosed patients with AF with or without co-morbid CAD. CAD adds to the disease burden of AF with increased crude rates of vascular mortality and MI compared to patients without CAD. Stroke, major bleed and intracranial bleed rates between groups were similar. Overall, over up to 2 years of treatment, the incidence rates of the assessed clinical events including stroke, major bleeding and MI were low with dabigatran, also among patients with CAD, confirming the long-term safety and effectiveness of dabigatran in clinical practice.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are